THE INDIAN PHARMACIST Official Circular Pharmacy LogoTHE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
Foundational Pharmaceutical Sciences ARTICLE ID: KH-12 ⏱️ 9 min read 📅 Updated: 2026-11-10

Industrial Pharmaceutics: Tablet Excipients, Granulation, Coating & Compaction Defects

🎯 Key Takeaways Summary

  • Avoid Lactose with primary amine drugs (e.g., Amlodipine, Fluoxetine, Amphetamines) due to Maillard browning discolouration; use MCC or Dicalcium Phosphate instead.
  • Enteric coating polymers (Cellulose Acetate Phthalate CAP, Eudragit L100/S100, HPMC Phthalate) resist gastric acid (pH 1.2 for 2 hours) and dissolve at duodenal pH >= 5.5–6.8.
  • Verify IP 2022 Weight Variation limits: +/- 10% for tablets <= 80 mg; +/- 7.5% for 80–250 mg; +/- 5% for >= 250 mg.

1. Foundational Clinical & Scientific Overview

Compressed tablets are the most widely dispensed pharmaceutical dosage form (>70% of all prescriptions) due to dosage accuracy, chemical/microbiological stability, tamper resistance, and patient convenience. Formulating a robust tablet requires functional excipients (diluents, binders, superdisintegrants, lubricants, glidants) and controlled powder engineering (Direct Compression, Wet Granulation, or Dry Roller Compaction).

2. Core Mechanisms, Classification & Practical Framework

During high-speed rotary tablet compression, granules fill the die cavity by gravity/force feeder, undergo pre-compression de-aeration, main compression consolidation (plastic deformation in ductile excipients like Microcrystalline Cellulose vs brittle fragmentation in Lactose/Dicalcium Phosphate), and ejection.

Structured Classification & Practical Examples

  • Diluents / Fillers: Lactose monohydrate (Maillard reaction with primary amines!), Microcrystalline Cellulose (MCC / Avicel), Mannitol (negative heat of solution for chewable/ODT tablets), Dibasic Calcium Phosphate.
  • Binders (Dry/Wet Granulation): Povidone (PVP K30), Hydroxypropyl Methylcellulose (HPMC), Starch paste.
  • Superdisintegrants (2%–5% w/w): Croscarmellose Sodium (Ac-Di-Sol), Crospovidone (Polyplasdone), Sodium Starch Glycolate (Primojel).
  • Lubricants & Glidants: Magnesium Stearate (0.25%–1% hydrophobic boundary lubricant; over-mixing delays dissolution and reduces tablet hardness!), Colloidal Silicon Dioxide (Aerosil, 0.1%–0.5% glidant).

3. Advanced Clinical Pharmacy, Dosing & Indian Regulatory Application

Root-Cause Diagnosis of Tablet Compaction & Coating Defects: (1) Capping (partial/complete separation of top/bottom crown) and Lamination (splitting into horizontal layers) result from air entrapment in overly fine powder blends, excessive compression speed, insufficient binder, or deep concave punches — remedied by pre-compression, proper granulation moisture, and reducing turret speed. (2) Picking (adhesion of tablet face to punch lettering) and Sticking (adhesion to die wall) result from excessive granule moisture or low-melting APIs (e.g., Ibuprofen). (3) Mottling (uneven colour distribution) arises from dye migration during drying. (4) Indian Pharmacopoeia (IP 2022) Quality Control Standards: Disintegration time <= 15 min (uncoated tablets), <= 30 min (film-coated), <= 3 min (dispersible/orodispersible); Friability <= 1.0% w/w after 100 revolutions at 25 rpm in Roche Friabilator.

4. Common Misunderstandings & Pharmacist Safety Safeguards

⚠️ Clinical Pitfall & Safety Note: Common Misunderstanding: Blending Magnesium Stearate with granules for 20–30 minutes alongside other excipients. Because Magnesium Stearate is a hydrophobic laminar lubricant, prolonged shear mixing coats individual granules in a waterproof film, drastically retarding water penetration, prolonging disintegration time, and reducing tensile strength; it must always be added last for a brief 2–3 minute lubrication blend.

5. Explanatory Visual Pharmacology Diagram (svg-v339-07-routes-of-drug-administration)

ROUTE-SPECIFIC DRUG DELIVERY: ONSET, BIOAVAILABILITY (F) & FIRST-PASS BYPASS 1. Oral (PO) • Onset: 30–90 min • F: Variable (5–99%) • First-Pass: YES (High) Safest, convenient; requires dissolution & portal transit. 2. Sublingual (SL) • Onset: 1–3 min (Rapid) • Drains to SVC directly • First-Pass: BYPASSED e.g. Sublingual GTN 0.5 mg in acute angina pectoris. 3. Buccal Route • Onset: 3–10 min • Cheek pouch mucosa • First-Pass: BYPASSED e.g. Buccal Midazolam, Buprenorphine, Fentanyl. 4. Intravenous (IV) • Onset: 15–60 sec • Bioavailability F = 100% • First-Pass: BYPASSED Strict asepsis & tonicity; irreversible once injected. 5. Intramuscular (IM) • Onset: 10–20 min • F: 75–100% • First-Pass: BYPASSED Deltoid / Vastus lateralis; oily depot formulations. 6. Subcutaneous (SC) • Onset: 15–30 min • Slow sustained absorption • First-Pass: BYPASSED Insulins, Enoxaparin (LMWH); rotate injection sites. 7. Inhalational • Onset: 2–5 min • Particle size 1–5 μm • Targeted Pulmonary Salbutamol, ICS; rinse mouth after ICS to prevent thrush. 8. Transdermal Patch • Onset: Hours (Steady) • Stratum corneum barrier • First-Pass: BYPASSED Fentanyl, GTN, Nicotine, Rivastigmine patches. 9. Topical / Ophthalmic • Local skin/mucosal effect • Minimal systemic toxicity • Nasolacrimal occlusion Timolol eye drops bypass first-pass if absorbed systemically. 10. Rectal (PR) • Onset: 5–30 min • Useful in vomiting/seizure • ~50% First-Pass Bypass Rectal Diazepam in paediatric febrile status epilepticus.
8.7 Route-Specific Drug Delivery: Bioavailability, Onset & First-Pass Comparison Across 10 Routes: Figure 8.7: Comparative biopharmaceutics across 10 routes of administration: Oral, Sublingual, Buccal, Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), Inhalational, Transdermal, Topical, and Rectal.

6. Authoritative References & Editorial Traceability

Primary Reference Sources: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) by Tejas Nartam; ICMR Standard Treatment Workflows; NFI & NLEM 2022.

Official Portals: CDSCO • Indian Pharmacopoeia Commission (IPC / NFI) • ICMR • FSSAI • NCBI Bookshelf

Educational Disclaimer: Published for pharmacy education, academic learning, and professional clinical reference. Never self-medicate or alter prescribed treatment without consulting a qualified medical practitioner.

← Previous: Biopharmaceutics, BCS Classification, Diss... All 40 Articles Next: Sterile Parenteral Formulations, Isotonici... →